Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2

Article  PubMed  Google Scholar 

Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F (2023) Italian Liver Cancer (ITA.LI.CA) group Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut 72(1):141–152. https://doi.org/10.1136/gutjnl-2021-324915

Article  PubMed  Google Scholar 

Toh MR, Wong EYT, Wong SH, Ng AWT, Loo L-H, Chow PK-H, Ngeow J (2023) Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology 164(5):766–782. https://doi.org/10.1053/j.gastro.2023.01.033

Article  PubMed  Google Scholar 

Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH (2023) AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78(6):1922–1965. https://doi.org/10.1097/HEP.0000000000000466

Article  PubMed  Google Scholar 

Gong W, Wu J, Wei H, Jiang Z, Wan M, Wu C, Xue W, Ma R, Zhou X, Zhou H (2023) Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients. Radiol Med 128(4):393–401. https://doi.org/10.1007/s11547-023-01614-9

Article  PubMed  Google Scholar 

Cellina M, Cè M, Rossini N, Cacioppa LM, Ascenti V, Carrafiello G, Floridi C (2023) Computed tomography urography: state of the art and beyond. Tomography 9(3):909–930. https://doi.org/10.3390/tomography9030075

Article  PubMed  PubMed Central  Google Scholar 

Ruan SM, Huang H, Cheng MQ, Lin MX, Hu HT, Huang Y, Li MD, Lu MD, Wang W (2023) Shear-wave elastography combined with contrast-enhanced ultrasound algorithm for noninvasive characterization of focal liver lesions. Radiol Med 128(1):6–15. https://doi.org/10.1007/s11547-022-01575-5

Article  PubMed  Google Scholar 

Cellina M, Cacioppa LM, Cè M, Chiarpenello V, Costa M, Vincenzo Z, Pais D, Bausano MV, Rossini N, Bruno A, Floridi C (2023) Artificial intelligence in lung cancer screening: the future is now. Cancers (Basel) 15(17):4344. https://doi.org/10.3390/cancers15174344

Article  CAS  PubMed  Google Scholar 

Cacioppa LM, Floridi C, Cocozza MA, Bruno A, Modestino F, Martella C, Rosati M, Paccapelo A, Mosconi C, Candelari R (2023) The prominent role of percutaneous transarterial embolization in the treatment of anterior abdominal wall hematomas: the results of three high volume tertiary referral centers. Radiol Med 128(9):1125–1137. https://doi.org/10.1007/s11547-023-01678-7

Article  PubMed  PubMed Central  Google Scholar 

European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019

Article  Google Scholar 

Yamada A, Kamagata K, Hirata K, Ito R, Nakaura T, Ueda D, Fujita S, Fushimi Y, Fujima N, Matsui Y, Tatsugami F, Nozaki T, Fujioka T, Yanagawa M, Tsuboyama T, Kawamura M, Naganawa S (2023) Clinical applications of artificial intelligence in liver imaging. Radiol Med 128(6):655–667. https://doi.org/10.1007/s11547-023-01638-1

Article  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681–693. https://doi.org/10.1016/j.jhep.2021.11.018

Article  PubMed  Google Scholar 

Mosconi C, O’Rourke J, Kloeckner R, Sturm L, Golfieri R, Celsa C, Fateen W, Odisio BC, Garanzini EM, Peck-Radosavljevic M, Borghi A, Ma YT, Stoehr F, Bettinger D, Giuffrida P, Aithal GP, Lin YM, Spreafico C, Giampalma E, Johnson P, Cucchetti A (2023) Textbook outcome after trans-arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol 46(4):449–459. https://doi.org/10.1007/s00270-023-03375-4

Article  PubMed  Google Scholar 

Chen QW, Ying HF, Gao S, Shen YH, Meng ZQ, Chen H, Chen Z, Teng WJ (2016) Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 40(3):309–314. https://doi.org/10.1016/j.clinre.2015.07.008

Article  PubMed  Google Scholar 

Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31(4):426–432. https://doi.org/10.1200/JCO.2012.42.9936

Article  PubMed  Google Scholar 

Renzulli M, Brandi N, Argalia G, Brocchi S, Farolfi A, Fanti S, Golfieri R (2022) Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions. Radiol Med 127(2):129–144. https://doi.org/10.1007/s11547-022-01449-w

Article  PubMed  Google Scholar 

Lee HJ, Kim JW, Hur YH, Shin SS, Heo SH, Cho SB, Kang YJ, Lim HS, Seon HJ, Jeong YY (2017) Combined therapy of transcatheter arterial chemoembolization and radiofrequency ablation versus surgical resection for single 2–3 cm hepatocellular carcinoma: a propensity-score matching analysis. J Vasc Interv Radiol 28(9):1240-1247.e3. https://doi.org/10.1016/j.jvir.2017.05.015

Article  PubMed  Google Scholar 

Dan Y, Meng W, Li W, Chen Z, Lyu Y, Yu T (2022) Transarterial chemoembolization combined with radiofrequency ablation versus hepatectomy for hepatocellular carcinoma: a meta-analysis. Front Surg 9:1–13. https://doi.org/10.3389/fsurg.2022.948355

Article  Google Scholar 

Ni JY, Liu SS, Xu LF, Sun HL, Chen YT (2013) Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 19(24):3872–3882. https://doi.org/10.3748/wjg.v19.i24.3872

Article  PubMed  PubMed Central  Google Scholar 

Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C (2021) Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. BMC Gastroenterol 21(1):1–10. https://doi.org/10.1186/s12876-021-01765-x

Article  CAS  Google Scholar 

Jiang C, Cheng G, Liao M, Huang J (2021) Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol 19(1):1–13. https://doi.org/10.1186/s12957-021-02188-4

Article  Google Scholar 

Lee SK, Yang H, Kwon JH, Shim DJ, Kim D, Nam SW, Yoo SH, Bae SH, Lee A, Lee YJ, Jeon C, Jang JW, Sung PS, Chun HJ, Kim SH, Choi JI, Oh JS, Yang YJ (2023) Chemoembolization combined radiofrequency ablation versus chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial. Trials 24(1):1–9. https://doi.org/10.1186/s13063-023-07266-4

Article  Google Scholar 

Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72(2):288–306. https://doi.org/10.1016/j.jhep.2019.09.026

Article  PubMed  Google Scholar 

Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL (2017) Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol 40(8):1141–1146. https://doi.org/10.1007/s00270-017-1703-4

Article  CAS  PubMed  Google Scholar 

Vacirca A, Faggioli G, Pini R, Gallitto E, Mascoli C, Cacioppa LM, Gargiulo M, Stella A (2019) The outcome of technical intraoperative complications occurring in standard aortic endovascular repair. Ann Vasc Surg 56:153–162. https://doi.org/10.1016/j.avsg.2018.08.092

Article  PubMed  Google Scholar 

Wang X, Hu Y, Ren M, Lu X, Lu G, He S (2016) Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol 17(1):93–102. https://doi.org/10.3348/kjr.2016.17.1.93

Article  PubMed  PubMed Central  Google Scholar 

Long J, Wang H, Zhao P, Sheng SP, Shi Q-S, Long M, Zheng JS (2020) Transarterial chemoembolization combined with radiofrequency ablation for solitary large hepatocellular carcinoma ranging from 5 to 7 cm: an 8-year prospective study. Abdom Radiol (NY) 45(9):2736–2747. https://doi.org/10.1007/s00261-020-02612-5

Article  PubMed  Google Scholar 

Ren Y, Cao Y, Ma H, Kan X, Zhou C, Liu J, Shi Q, Feng G, Xiong B, Zheng C (2019) Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. BMC Cancer 19(1):1–10. https://doi.org/10.1186/s12885-019-6237-5

Article  CAS